We endorse that, in treating DKA patients with profound hypokalemia (K<3.3mM/L), it is essential to start enteral and parenteral potassium simultaneously with the initiation of insulin infusion at a lower rate to treat the culprit of hypokalemia, to treat DKA, and to avoid any insulin infusion delays in attempting to correct ongoing hypokalemia. The gene discussed is INS; the disease is Hypokalemia.